Table 2. Distributions of KRAS mutations in the selected patients.

Clinical characteristic	n	KRAS mutation (n%)	Univariate OR (95%CI)	Multivariate OR (95%CI)
Total	495	143(28.9%)
gender
women	184	50(27.1%)	1(reference)	1(reference)
men	311	93(29.9%)	1.1(0.8-1.7)	1.2(0.8-1.8)
age
≤53	137	27(19.7%)	1(reference)	1(reference)
54-60	124	36(29.0%)	1.7(1.0-3.0)	1.6(0.9-3.0)
61-66	119	46(38.6%)	2.6(1.5-4.5)	2.3(1.3-4.1)
>66	115	33(28.6%)	1.6(0.9-2.9)	1.5(0.8-2.7)
location
Right colon	149	46(30.9%)	1(reference)	1(reference)
Left colon	346	97(28.0%)	0.9(0.6-1.3)	0.9(0.5-1.4)
histology
TA	155	24(15.5%)	1(reference)	1(reference)
TVA	123	46(37.4%)	3.3(1.8-5.8)	3.0(1.7-5.4)
SA	52	12(23.1%)	1.6(0.8-3.6)	1.5(0.7-3.2)
VA	7	3(43.0%)	4.1(0.9-19.4)	3.8(0.8-18.4)
HPs	65	20(30.8%)	2.4(1.2-4.8)	2.3(1.2-4.6)
HGIN	93	38(40.9%)	3.8(2.1-6.9)	3.5(1.9-6.5)

TA= Tubular adenoma, TVA= Tubulovillous adenoma, SA= Serrated adenoma, VA= Villous adenoma, HPs= Hyperplastic polyps, HGIN= High grade intraepithelial neoplasia